Sprycel faces multi-pronged challenge as India presses for compulsory licence
This article was originally published in Scrip
The patient-versus-patent debate in India is set to reach another crescendo, this time with Bristol-Myers Squibb's anticancer Sprycel (dasatinib) under the glare as a potential second candidate for a drug compulsory license (CL) in the country.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…